plant
cell
ideal
bioreactor
product
oral
deliveri
vaccin
biopharmaceut
elimin
need
expens
ferment
purif
cold
storag
transport
steril
deliveri
plantmad
vaccin
develop
two
decad
none
advanc
beyond
phase
howev
two
plantmad
biopharmaceut
advanc
phase
ii
phase
iii
human
clinic
trial
review
evalu
advantag
disadvantag
differ
plant
express
system
stabl
nuclear
chloroplast
transient
viral
current
limit
challeng
provid
suggest
advanc
valuabl
concept
clinic
applic
conclud
greater
research
emphasi
need
largescal
product
purif
function
character
oral
deliveri
preclin
evalu
need
new
platform
product
therapeut
protein
approxim
million
million
death
per
year
worldwid
estim
relat
directli
infecti
diseas
vaccin
consid
effici
costeffect
mean
health
intervent
combat
infecti
diseas
howev
high
cost
vaccin
make
unafford
peopl
live
develop
countri
daili
averag
incom
nearli
one
billion
peopl
us
increas
cost
vaccin
past
decad
make
necessari
investig
altern
strategi
product
deliveri
also
emphasi
safeti
increas
shift
toward
develop
subunit
vaccin
use
one
two
protein
instead
avirul
kill
pathogen
strain
relianc
recombin
express
system
high
cost
current
vaccin
biopharmaceut
larg
result
complex
product
deliveri
method
includ
signific
cost
ferment
purif
system
addit
expens
associ
adjuv
cold
storag
transport
steril
deliveri
viabl
altern
ferment
technolog
yet
emerg
mass
product
void
could
address
use
plant
bioreactor
product
oral
deliveri
therapeut
protein
review
evalu
advantag
disadvantag
differ
plant
express
system
stabl
nuclear
transient
viral
stabl
chloroplast
current
limit
challeng
ahead
discuss
direct
advanc
valuabl
concept
clinic
applic
plantmad
therapeut
protein
current
statu
challeng
ahead
plantmad
vaccin
therapeut
refer
protein
product
clinic
veterinari
applic
produc
recombin
plant
system
system
broadli
divid
use
nuclear
transgen
technolog
chloroplast
transplastom
technolog
plant
viral
technolog
figur
case
antigen
therapeut
express
plant
tissu
either
purifi
plant
tissu
process
form
appli
topic
uniqu
oral
major
advantag
plant
express
system
vaccin
product
system
reduc
manufactur
cost
ferment
bioreactor
replac
contain
plant
growth
room
greenhous
plant
grown
field
appropri
biolog
contain
foreign
gene
matern
inherit
male
steril
express
veget
tissu
harvest
appear
reproduct
structur
lead
reduc
upstream
facil
cost
case
oral
plantproduc
vaccin
therapeut
downstream
process
cost
also
reduc
instead
protein
purif
target
puriti
plant
tissu
inexpens
process
oral
deliveri
relev
technolog
alreadi
develop
food
feed
industri
adapt
plantproduc
therapeut
protein
eukaryot
system
plantproduc
vaccin
enabl
introduct
posttransl
modif
proper
fold
disulfid
bond
format
occur
chloroplast
endoplasm
reticulum
er
proper
lipid
modif
vaccin
antigen
also
observ
chloroplast
therapeut
protein
glycosyl
chloroplast
glycosyl
target
er
although
glycosyl
pattern
ident
mammalian
system
although
numer
therapeut
protein
express
plant
cell
tabl
appendix
btabl
supplementari
materi
onlin
sever
challeng
remain
transgen
silenc
nuclear
transgen
plant
requir
investig
improv
tool
need
transgen
contain
facilit
field
product
vaccin
biopharmaceut
express
via
nuclear
genom
gener
express
level
target
depend
challeng
recombin
system
mani
function
assay
host
cell
protein
yet
develop
inject
product
despit
activ
research
limit
publish
work
highli
purifi
protein
character
contamin
well
known
express
level
vari
depend
development
stage
leav
time
day
regulatori
sequenc
use
underscor
import
development
stage
plant
time
harvest
importantli
achiev
consist
transgen
express
differ
batch
import
challeng
therefor
harvest
leav
homogen
level
therapeut
protein
must
determin
harvest
batch
limit
studi
determin
stabil
therapeut
protein
harvest
process
storag
remov
agrobacteria
vacuum
infiltr
viral
vector
yet
anoth
challeng
concern
need
address
care
reproduc
investig
current
focu
group
purifi
antigen
prepar
plant
grown
contain
condit
avoid
environment
releas
enabl
control
plant
trend
plant
scienc
growth
decreas
cost
advantag
versu
fieldgrown
plant
construct
greenhous
growth
room
meet
regulatori
approv
rel
expens
case
oral
deliveri
move
forward
promis
veterinari
candid
lay
foundat
human
vaccin
determin
regulatori
pathway
oral
product
major
hurdl
given
limit
resourc
promin
research
group
field
purifi
vaccin
therapeut
protein
might
follow
similar
regulatori
path
recombin
protein
produc
system
focu
stabil
potenc
efficaci
purifi
product
purifi
protein
subunit
vaccin
adjuv
need
must
develop
alongsid
target
antigen
japanes
enceph
viru
jev
envelop
protein
e
rice
mg
mg
tsp
jev
specif
neutral
antibodi
detect
mice
follow
intraperiton
oral
administr
protozoan
antigen
plasmodium
yoelii
merozoit
surfac
protein
tobacco
tsp
induc
antigenspecif
antibodi
mice
follow
parenter
deliveri
human
vaccin
viraltransi
express
bacteri
antigen
yersinia
pesti
lcrv
antigen
tobacco
leaf
tissu
mg
g
fw
immunogen
protect
monkey
pesti
follow
subcutan
inject
yersinia
pesti
antigen
tobacco
leaf
mg
g
immunogen
protect
vaccin
guinea
pig
pesti
aerosol
challeng
viral
antigen
smallpox
recombin
vaccin
viru
antigen
domain
tobacco
leaf
report
antibodi
respons
mice
immun
parenter
protect
lethal
dose
vaccinia
viru
encod
domain
iii
dengu
envelop
protein
tobacco
tsp
retain
antigen
immunogen
well
induc
neutral
antibodi
vaccin
anim
hiv
entri
inhibitor
red
algal
protein
griffithsin
grft
tobacco
tmv
g
kg
fw
activ
hiv
picomolar
concentr
directli
virucid
via
bind
hiv
envelop
glycoprotein
capabl
block
celltocel
hiv
transmiss
pathogen
avian
influenza
viru
subtyp
tobacco
mg
kg
fw
immunogen
mice
ferret
also
protect
ferret
challeng
infect
viru
review
trend
plant
scienc
past
two
decad
vaccin
antigen
express
via
plant
nuclear
genom
elicit
appropri
immunoglobulin
respons
confer
protect
upon
oral
deliveri
transgen
plantbas
vaccin
yet
move
beyond
phase
clinic
trial
howev
least
two
therapeut
develop
biolex
http
wwwbiolexcom
protalix
http
wwwprotalix
com
move
phase
ii
phase
iii
earliest
research
use
plant
recombin
express
vaccin
antigen
perform
use
stabl
transform
nuclear
genom
tobacco
nicotiana
tobacum
eas
nuclear
transgen
methodolog
start
agrobacteriummedi
deliveri
dna
facilit
approach
domin
strategi
sever
year
advantag
includ
abil
scale
product
larg
amount
vaccin
antigen
transgen
seed
stock
possibl
express
fruit
edibl
plant
organ
enabl
oral
deliveri
minim
process
materi
howev
stabli
integr
nuclear
transgen
typic
yield
rel
low
level
express
total
solubl
protein
tsp
appendix
btabl
supplementari
materi
onlin
vari
plant
plant
gener
gener
probabl
owe
gene
silenc
posit
effect
mani
differ
vaccin
antigen
produc
variou
plant
speci
includ
tobacco
edibl
plant
eg
solanum
tuberosum
solanum
lycopersicum
zea
may
daucu
carota
glycin
max
tabl
appendix
btabl
supplementari
materi
onlin
oral
deliveri
sever
plantderiv
antigen
elicit
antigenspecif
antibodi
mice
clinic
trial
human
vaccin
antigen
deriv
enter
pathogen
norwalk
viru
capsid
protein
nvcp
rotaviru
capsid
protein
bacteri
gangliosidebind
protein
cholera
toxin
b
subunit
ctb
escherichia
coli
heatlabil
toxin
b
subunit
ltb
extens
evalu
nuclear
transgen
plant
appendix
btabl
supplementari
materi
onlin
exampl
mice
oral
immun
carrotderiv
ltb
ricederiv
ctb
induc
protect
cholera
toxin
ct
challeng
sever
antigen
nonenter
pathogen
f
protein
respiratori
syncyti
viru
surfac
antigen
hepat
b
also
stimul
antigenspecif
antibodi
oral
deliveri
howev
adjuv
might
requir
stimul
exampl
case
hepat
b
surfac
antigen
hbsag
fed
mice
transgen
potato
tuber
necessari
use
ct
potent
mucos
adjuv
stimul
signific
level
antihbsag
antibodi
although
hbsag
potato
fed
human
without
adjuv
provok
serum
antihbsag
volunt
given
potato
plant
organ
except
seed
limit
shelf
life
fresh
state
vaccin
dosag
must
care
monitor
unlik
fresh
unprocess
plant
materi
use
vaccin
thu
form
process
freezedri
fruit
plant
organ
must
use
produc
product
batch
valid
potenc
stabil
nvcp
demonstr
either
freezeor
airdri
transgen
tomato
fruit
yield
materi
least
oral
immunogen
fresh
transgen
tomato
howev
freezedri
potato
nvcp
produc
poor
result
compar
fresh
potato
nvcp
oxid
phenol
compound
dri
potato
probabl
caus
problem
thu
control
oxid
import
issu
tissu
rich
phenol
enzym
polyphenol
oxidas
use
use
seed
tissu
promis
materi
demonstr
extend
stabil
human
anim
vaccin
candid
seedbas
vaccin
particularli
attract
develop
veterinari
product
conveni
storag
deliveri
shown
promis
result
farm
anim
studi
develop
plant
viral
vector
system
transient
express
enabl
rapid
express
recombin
protein
level
higher
stabli
integr
nuclear
transgen
tabl
appendix
btabl
supplementari
materi
onlin
tobacco
mosaic
viru
although
rna
viru
replic
cytosol
deliv
dna
construct
transcrib
nucleu
produc
viral
rna
one
iter
magnicon
technolog
use
express
hepat
b
core
antigen
hbsag
nvcp
plagu
antigen
v
level
mg
g
fresh
leaf
mass
nicotiana
benthamiana
similar
launch
vector
technolog
rang
candid
includ
influenza
target
express
high
level
n
benthamiana
given
tobacco
close
rel
n
benthamiana
usual
host
system
vector
gener
introduc
vacuum
infiltr
agrobacteria
product
must
purifi
deliveri
vaccin
ensur
remov
noxiou
host
plant
compound
remov
agrobacteria
howev
purif
necessari
solubl
antigen
might
lose
oral
immunogen
owe
remov
encapsul
effect
might
help
protect
harsh
stomach
environ
nonetheless
nvcp
partial
purifi
leav
induc
serum
igg
mucos
iga
respons
oral
deliveri
mice
one
approach
could
overcom
limit
express
vaccin
antigen
viruslik
particl
follow
nonvir
base
transient
express
system
promis
immunogen
result
follow
inject
purifi
influenza
antigen
might
extend
oral
deliveri
dna
replicon
system
develop
use
geminiviru
bean
yellow
dwarf
viru
beydv
construct
deliv
agroinfiltr
similar
magnicon
launch
vector
system
similar
launch
vector
system
use
singl
vector
wherea
magnicon
system
requir
three
separ
vector
express
hbcag
nvcp
rang
mg
g
leaf
mass
observ
beydv
replicon
similar
obtain
magnicon
system
magnicon
system
also
adapt
igg
express
requir
combin
tmv
tobacco
mosaic
viru
replicon
potato
viru
x
replicon
five
differ
agrobacterium
vector
beydv
replicon
also
stabli
incorpor
nuclear
genom
induc
promot
drive
viral
rep
gene
control
gene
amplif
tenfold
increas
express
nvcp
cultur
tobacco
cell
obtain
induct
system
might
enabl
use
stabl
transgen
line
improv
express
recombin
pharmaceut
protein
use
treatment
variou
condit
genet
diseas
result
product
insuffici
quantiti
qualiti
particular
protein
given
mani
protein
would
administ
parenter
high
degre
purif
current
good
manufactur
practic
condit
necessari
human
use
nuclear
transgen
plant
strategi
use
mani
studi
demonstr
product
mani
valuabl
human
protein
includ
epiderm
growth
factor
serum
albumin
interferon
interleukin
lysozym
lactoferrin
human
acid
bglucosidas
tabl
appendix
btabl
supplementari
materi
onlin
howev
vaccin
antigen
express
level
gener
low
specif
assay
demonstr
activ
recombin
protein
vitro
cellbas
assay
extens
anim
studi
yet
publish
although
plant
cell
synthes
process
mammalian
protein
case
plantspecif
glycosyl
eror
cell
surfacetarget
protein
might
produc
undesir
immunogen
recombin
protein
could
diminish
halflif
util
bglucosidas
produc
seed
tobacco
lack
plantspecif
xylos
review
trend
plant
scienc
fucos
residu
problemat
seedbas
express
eror
cell
surfacetarget
protein
yield
similar
result
target
recombin
protein
seed
storag
vacuol
advantag
er
retent
protein
ctermin
inclus
kdel
kdellik
tag
serv
limit
glycosyl
recombin
protein
core
glycan
structur
comparison
cell
surfacetarget
protein
also
recent
advanc
plant
glycan
engin
hold
promis
broadli
applic
product
pharmaceut
glycoprotein
plant
addit
pharmaceut
protein
human
growth
hormon
human
fibroblast
growth
factor
human
diabetesassoci
autoantigen
etc
produc
plant
use
transient
express
system
subcellular
target
option
chloroplast
technolog
foreign
gene
integr
chloroplast
genom
homolog
recombin
elimin
variat
express
among
independ
transgen
line
moreov
gene
silenc
yet
report
chloroplast
transgen
transplastom
line
high
level
express
vaccin
antigen
facilit
copi
transgen
transform
plant
cell
chloroplast
express
minim
risk
foreign
gene
transfer
via
pollen
genet
modifi
crop
relat
crop
weed
owe
matern
inherit
transgen
addit
express
therapeut
protein
leav
facilit
harvest
develop
reproduct
structur
offer
addit
opportun
contain
therefor
sever
chloroplastderiv
vaccin
antigen
biopharmaceut
protein
grown
field
condit
least
one
studi
publish
date
vaccin
antigen
differ
diseas
biopharmaceut
protein
express
chloroplast
tabl
appendix
btabl
supplementari
materi
onlin
presenc
chaperon
posttransl
modif
enzym
chloroplast
creat
nich
target
process
assembl
suitabl
posttransl
modif
assembl
multim
disulfid
bond
lipid
modif
etc
although
glycosyl
option
nglycosyl
known
occur
within
chloroplast
chloroplast
express
system
use
produc
sever
fulli
function
vaccin
antigen
bacteri
viral
protozoan
pathogen
tabl
appendix
btabl
supplementari
materi
onlin
protein
difficult
express
system
antimicrobi
protein
also
express
chloroplast
addit
plant
chlamydomona
chloroplast
use
express
therapeut
protein
although
achiev
higher
level
express
major
challeng
recent
improv
system
inde
adequ
level
express
therapeut
protein
chloroplast
alway
possibl
protein
evalu
function
tabl
appendix
btabl
supplementari
materi
onlin
one
major
limit
field
sever
vaccin
antigen
therapeut
protein
express
tobacco
tobacco
edibl
addict
nicotin
also
make
unsuit
oral
deliveri
therapeut
protein
altern
carrot
plastid
transform
system
develop
adequ
level
gene
express
edibl
tissu
facilit
oral
deliveri
howev
carrot
regener
slow
suitabl
rapid
product
therapeut
protein
although
adequ
express
human
immun
defici
viru
hiv
antigen
observ
tomato
leav
reduct
green
fruit
express
observ
ripe
fruit
lettuc
lactuca
sativa
l
chloroplast
transform
also
develop
success
express
first
therapeut
protein
proinsulin
lettuc
chloroplast
recent
system
optim
sever
therapeut
protein
express
level
express
lettuc
chloroplast
similar
tobacco
chloroplast
regener
rapid
tobacco
thu
open
door
practic
oral
deliveri
chloroplast
express
protein
anoth
challeng
oral
deliveri
chloroplastderiv
protein
adequ
dose
confer
immun
case
autoantigen
induc
toler
context
demonstr
chloroplastderiv
therapeut
protein
deliv
oral
via
plant
cell
protect
degrad
stomach
presum
bioencapsul
antigen
plant
cell
wall
facilit
transloc
vaccin
antigen
therapeut
gut
lumen
circulatori
system
target
protein
fuse
ctb
transmucos
carrier
protein
bind
epitheli
receptor
gm
approach
wide
appli
mani
oral
deliv
antigen
stabl
nuclear
transgen
transplastom
approach
sever
vaccin
antigen
bacteri
diseas
produc
chloroplast
tabl
appendix
btabl
supplementari
materi
onlin
ctb
subunit
first
vaccin
express
chloroplast
shown
function
gm
bind
assay
subsequ
fusion
ltb
heatstabl
toxin
st
express
tobacco
chloroplast
mice
immun
chloroplastderiv
ltbst
fusion
protein
partli
protect
ct
challeng
recent
two
ctb
fusion
protein
express
tobacco
lettuc
chloroplast
subcutan
oral
administ
mice
chloroplastderiv
ctb
fusion
protein
protect
ct
challeng
high
level
serum
intestin
ctbiga
detect
oral
administ
mice
although
none
mice
administ
antigen
subcutan
detect
ctbiga
high
level
titer
confer
protect
ct
challeng
compar
pattern
express
observ
oral
administ
mice
addit
intestin
serum
iga
confer
protect
confirm
oral
vaccin
result
mucos
system
immun
respons
importantli
longterm
immun
protect
mous
lifespan
observ
signific
advanc
immun
lost
current
cholera
vaccin
review
trend
plant
scienc
children
within
year
fulli
protect
adult
vaccin
antigen
tetanu
also
confer
complet
protect
pathogen
challeng
although
chloroplastderiv
outer
surfac
lipoprotein
ospa
gener
lower
level
protect
antibodi
compar
lipid
escherichia
colideriv
ospa
gener
antibodi
level
could
protect
lyme
diseas
chloroplast
transform
system
use
success
develop
vaccin
bioterror
agent
current
avail
anthrax
vaccin
obtain
cultur
bacillu
anthraci
undesir
side
effect
local
pain
edema
rel
high
rate
local
system
reaction
includ
inflamm
flulik
symptom
attempt
produc
anthrax
vaccin
larg
quantiti
free
extran
bacteri
contamin
protect
antigen
pa
express
transgen
tobacco
chloroplast
insert
paga
gene
chloroplast
genom
high
level
igg
titer
report
mice
immun
subcutan
partial
purifi
chloroplastderiv
pa
anim
surviv
lethal
dose
toxin
challeng
estim
million
dose
fulli
function
anthrax
vaccin
could
produc
one
acr
tobacco
contrast
approv
vaccin
bubon
pneumon
plagu
potenti
agent
bioterror
recent
plagu
fusion
antigen
express
chloroplast
function
investig
mice
anim
immun
either
subcutan
oral
chloroplastderiv
protect
antigen
show
significantli
higher
level
serum
specif
titer
subcutan
immun
mice
surviv
contrast
oral
immun
mice
protect
heavi
dose
aerosol
yersinia
pesti
plagu
challeng
comparison
splenic
pesti
cfu
count
show
reduct
mean
bacteri
burden
survivor
show
oral
deliveri
offer
greater
protect
immun
demonstr
oral
deliveri
chloroplastderiv
vaccin
effect
mode
deliveri
plantderiv
vaccin
antigen
first
viral
antigen
capabl
elicit
protect
immun
respons
express
chloroplast
canin
parvoviru
cpv
mice
immun
intraperiton
chloroplastderiv
fuse
ctb
leaf
extract
elicit
antibodi
furthermor
antibodi
induc
rabbit
plant
extract
effici
neutral
cpv
infect
crfk
cell
structur
protein
neutral
antigen
classic
swine
fever
viru
csfv
express
tobacco
chloroplast
subcutan
immun
induc
serum
antibodi
reaction
csfv
howev
immun
respons
detect
oral
immun
contrast
studi
describ
shown
chloroplastderiv
subunit
vaccin
hepat
e
viru
peptid
induc
antibodi
subcutan
immun
mice
also
major
structur
protein
human
papillomaviru
capsid
express
tobacco
chloroplast
genom
chloroplastderiv
protein
display
conformationspecif
epitop
assembl
viruslik
particl
visibl
transmiss
electron
microscopi
furthermor
chloroplastderiv
protein
show
immunogen
neutral
antibodi
mice
inject
intraperiton
chloroplastderiv
protozoan
antigen
potenti
antiamoeb
candid
leca
surfac
antigen
entamoeba
histolytica
express
tobacco
chloroplast
result
high
immunogen
mice
follow
subcutan
administr
report
million
dose
vaccin
antigen
produc
per
acr
transplastom
plant
recent
malaria
vaccin
candid
fuse
ctb
express
tobacco
lettuc
chloroplast
signific
level
antigenspecif
titer
oral
subcutan
immun
mice
immunoblot
immunofluoresc
studi
shown
chloroplastderiv
inhibit
prolifer
malaria
parasit
crossreact
nativ
parasit
protein
schizont
ring
trophozoit
stage
vitro
parasit
inhibit
studi
show
mice
higher
antibodi
titer
exhibit
highest
inhibit
chloroplastderiv
autoantigen
type
diabet
result
autoimmun
destruct
insulinproduc
cell
current
treatment
expens
also
provid
transient
relief
recent
human
proinsulin
fuse
ctb
express
lettuc
tobacco
chloroplast
shown
pancrea
mice
immun
chloroplastderiv
ctbproinsulin
decreas
infiltr
cell
characterist
lymphocyt
insul
significantli
preserv
insulinproduc
bcell
pancreat
islet
lower
blood
urin
glucos
level
moreov
increas
express
immunosuppress
cytokin
observ
pancrea
chloroplastderiv
ctbproinsulin
treat
mice
indic
thelper
lymphocytemedi
oral
toler
anoth
autoantigen
prevent
delay
onset
glutam
acid
decarboxylas
express
chlamydomona
chloroplast
recombin
react
sera
nonobes
diabet
mice
stimul
prolifer
spleen
lymphocyt
mice
chloroplastderiv
human
blood
protein
sever
chloroplastderiv
pharmaceut
protein
produc
tabl
appendix
btabl
supplementari
materi
onlin
exampl
human
somatotropin
express
tobacco
chloroplast
function
shown
use
rat
lymphoma
cell
line
prolifer
assay
human
serum
albumin
express
tobacco
chloroplast
form
inclus
bodi
human
interferon
gamma
ifng
express
chloroplast
protect
human
lung
carcinoma
cell
line
review
trend
plant
scienc
vol
infect
encephalomyocard
viru
chloroplastderiv
similar
activ
commerci
produc
pegintron
tm
protect
cell
cytopath
viral
replic
vesicular
stomat
viru
cytopath
effect
assay
inhibit
earlystag
hiv
infect
increas
express
major
histocompat
complex
class
splenocyt
total
number
natur
killer
cell
purifi
transplastom
line
protect
mice
highli
metastat
tumor
line
follow
intraperiton
inject
human
express
tobacco
chloroplast
bind
porcin
pancreat
elastas
although
detail
function
evalu
need
insulinlik
growth
factor
express
tobacco
chloroplast
mass
spectrometri
confirm
ident
purifi
chloroplastderiv
human
biolog
activ
chloroplastderiv
commerci
synthes
human
similar
level
mitot
activ
shown
mammalian
cell
human
cell
prolifer
assay
proper
function
sever
human
blood
protein
show
requir
disulfid
bond
form
chloroplast
therefor
proper
posttransl
modif
function
activ
chloroplastderiv
therapeut
protein
open
door
product
lowcost
plant
base
therapeut
protein
deliv
oral
plantderiv
vaccin
biopharmaceut
advantag
need
expens
ferment
purif
system
expens
associ
cold
storag
transport
steril
deliveri
although
plantmad
vaccin
develop
advanc
two
decad
none
advanc
beyond
phase
human
clinic
trial
crucial
evalu
variou
express
system
highlight
advantag
disadvantag
system
stabl
nuclear
express
system
develop
three
decad
avail
larg
number
crop
abil
facilit
tissuespecif
express
induc
express
howev
seen
list
vaccin
antigen
biopharmaceut
express
via
nuclear
genom
appendix
btabl
supplementari
materi
onlin
express
level
often
inadequ
commerci
develop
although
adequ
express
antigen
advanc
clinic
trial
case
chloroplast
gener
offer
higher
level
express
vaccin
antigen
bacteri
viral
protozoan
pathogen
biopharmaceut
transgen
contain
via
matern
inherit
chloroplast
system
express
therapeut
protein
develop
past
year
recent
develop
effici
lettuc
chloroplast
system
oral
deliveri
signific
advanc
howev
glycoprotein
express
chloroplast
glycosyl
form
although
viral
express
system
produc
therapeut
protein
quickli
gener
suitabl
oral
deliveri
therefor
cost
associ
purif
cold
storag
transport
steril
deliveri
would
major
challeng
viral
system
downstream
process
cost
typic
product
cost
signific
challeng
futur
reduc
howev
research
viral
system
made
signific
progress
recent
includ
develop
antibodi
passiv
immun
nonhodgkin
lymphoma
phase
clinic
trial
test
plagu
vaccin
monkey
develop
antihiv
peptid
transient
express
technolog
well
suit
pandem
respons
face
influenza
strain
ultim
success
plantbas
product
system
subunit
vaccin
protein
therapeut
candid
probabl
depend
lead
commerci
viabl
target
success
transit
clinic
trial
next
year
plantbas
product
system
recombin
protein
research
past
year
prolifer
academ
group
biotechnolog
compani
togeth
group
larger
agrochem
compani
develop
express
technolog
lead
product
candid
effort
need
repaid
posit
result
later
clinic
studi
field
continu
advanc
notabl
earli
clinic
stage
success
record
advanc
sever
oral
edibl
vaccin
candid
phase
trial
howev
none
candid
product
progress
larg
either
repres
proofofprincipl
target
impract
oral
deliveri
vehicl
past
year
insuffici
fund
lack
commerci
interest
plantbas
oral
vaccin
led
approach
slow
oral
vaccin
candid
recent
enter
clinic
challeng
guid
novel
plantbas
oral
vaccin
regulatori
process
current
outweigh
avail
resourc
recent
increas
focu
use
plantbas
product
system
gener
purifi
recombin
protein
vaccin
therapeut
deliv
inject
notabl
recent
exampl
clinic
trial
success
includ
person
therapeut
vaccin
nonhodgkin
lymphoma
assess
phase
clinic
trial
combat
hepat
c
assess
phase
iia
clinic
trial
http
wwwbiolexcom
human
glucocerebrosidas
combat
gaucher
diseas
progress
phase
iii
clinic
trial
similar
purifi
protein
product
repres
current
best
option
make
plantbas
product
system
human
vaccin
therapeut
realiti
case
emphasi
demonstr
plant
product
system
gener
antigen
therapeut
protein
compar
safeti
potenc
efficaci
recombin
system
without
ad
concern
oral
recombin
plant
deliveri
vehicl
parallel
track
plantproduc
vaccin
candid
newcastl
diseas
chicken
approv
use
focus
protein
product
purifi
plant
cell
emphas
plantproduc
target
progress
along
regulatori
path
summari
avail
divers
plantbas
product
system
offer
opportun
produc
wide
array
antigen
biopharmaceut
protein
divers
diseas
differ
mean
deliveri
explor
howev
greater
research
emphasi
need
largescal
product
purif
function
character
trend
plant
scienc
oral
deliveri
preclin
evalu
field
move
forward
